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Since cisplatin, cis-diamminedichloroplatinum(II), received FDA approval for use in cancer treatment in
1978, platinum-based drugs have been one of the most widely used drugs for the treatment of tumors in
testicles, ovaries, head and neck. However, there are concerns associated with the use of platinum-based
anticancer drugs, owing to severe side eﬀects and drug resistance. In order to overcome these limitations,
various drug-delivery systems have been developed based on diverse organic and inorganic materials. In
particular, the versatility of polymeric materials facilitates the tuning of drug-delivery systems to meet
their primary goals. This review focuses on the progress made over the last ﬁve years in the application of
polymeric nanoparticles for the delivery of platinum-based anticancer drugs. The present article not only
describes the fundamental principles underlying the implementation of polymeric nanomaterials in plati-
num-based drug delivery, but also summarizes concepts and strategies employed in the development of
drug-delivery systems.
1. Introduction
Chemotherapy, i.e., the treatment of diseases by adminis-
tration of chemical compounds, is currently one of the most
eﬀective ways to treat cancer. Among a variety of anticancer
agents, cisplatin, a leading platinum (Pt)-based anticancer
drug, has been used for more than three decades, either as a
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single therapeutic agent or in combination with other
agents.1,2 Following the success of cisplatin, various Pt-based
drugs (Fig. 1) have been developed, although only a small
subset has received US Food and Drug Administration (FDA)
approval. Nowadays, they play a crucial role in the treatment of
various cancers, such as cancers in testicles, ovaries, head,
and neck.3–5 However, the use of Pt-based anticancer drugs is
associated with drug resistance and inactivation by vascular
and cellular components, and is associated with severe side
eﬀects incurred by the systemic delivery, such as nephrotoxi-
city, ototoxicity, neurotoxicity, and emetogenesis.6–9 Therefore,
various delivery systems have been developed to prevent the
shortcomings of Pt-based chemotherapy and to increase its
eﬃcacy.10–12
Approaches like carrier-based drug delivery generally exploit
the diﬀerence between normal and tumor tissues for increas-
ing the eﬃcacy and selectivity of a drug towards the target
tissue. More specifically, the enhanced permeability and reten-
tion (EPR) eﬀect is based on the increased permeability of
nano-sized macromolecules coupled with the poor lymphatic
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Fig. 1 Chemical structures of various Pt-based drugs. (A) Cisplatin, (B) oxaliplatin, (C) ZD0473, (D) BBR 3005, (E) satraplatin, (F) DACHPt, (G) mitapla-
tin and (H) camplatin.
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clearance and slow venous return in the tumor tissues.13–17
Long-circulating nanocarriers have greater chances to be
exposed to a tumor site, compared to low-molecular weight
drugs which are rapidly cleared from the circulation. Thus, the
EPR eﬀect results in passive targeting of drug-loaded nano-
particles to the tumor tissues. In some cases, this can be
further enhanced by active targeting, the use of nanoparticles
functionalized with ligands for selectively binding to tumor-
specific moieties exposed at the target cells.16–19 Such moieties
generally include transporters, antigens, or receptors whose
quantity or functionality is higher in tumors compared to
normal tissues. Drug-delivery systems based on nanocarriers
include micelles,20,21 liposomes,22 dendrimers,23 silica nano-
particles,24 and organic/inorganic hybrid nanoparticles.25 The
most fascinating features of polymer-based delivery systems
arise from the versatility of the polymer sources and their com-
binatorial synthesis. This versatility enables an easy tuning of
the properties of the nanoparticles to meet the purpose of
using delivery systems.21
For the successful drug delivery, drug encapsulation
eﬃciency is one of the important indexes, especially in the
case of poorly bioavailable drugs. To maximize the eﬃcacy of
anticancer drugs, the developed drug delivery systems must
contain large amounts of drugs as much as possible. The poly-
meric nanoparticles facilitate eﬃcient encapsulation of drugs
into the nanocarriers by exploiting the compatibility between
drugs and matrixes of polymeric nanoparticles or by employ-
ing the chemical conjugation between the polymeric backbone
and drugs. In addition, the nanoparticles must release the
drugs at a controlled rate. The controlled release of drugs has
been achieved through the utilization of stimuli-responsive
chemical bonds between drugs and the polymeric backbone or
among polymeric blocks comprising the nanoparticles. There-
fore, the ultimate goal of this review is to discuss the strategies
for loading Pt-based drugs into the polymeric nanoparticles
eﬃciently and for modulating their release in an appropriate
manner, which aﬀect significantly the anticancer eﬃcacy.
In this review, we discuss the progress in the field of poly-
meric delivery systems of Pt-based anticancer drugs over the
past five years. The article is organized into the following sec-
tions: first, we briefly introduce the characteristics of each
structurally diﬀerent Pt-based anticancer drug, involving both
Pt(II)- and Pt(IV)-based drugs; then, we systematically discuss
the encapsulation needed for delivering the Pt-based drugs;
finally, we highlight the conjugation methods used for deliver-
ing Pt(II)- and Pt(IV)-based drugs.
2. Structure and cellular mechanism
of Pt(II) and Pt(IV) compounds
Although numerous Pt-based drugs have been developed, most
of them can be categorized into two groups, based on Pt(II)
and Pt(IV), according to the molecular structure. As a back-
ground reference for the subsequent sections, here we provide
a comprehensive summary of the structure and cellular mech-
anism of Pt(II) and Pt(IV)-based drugs.
The most representative Pt(II)-based drug is cisplatin, which
is the cis isomer of the square planar configuration
(Fig. 1A).26,27 According to the HSAB (Hard–Soft Acid–Base)
theory, Pt can be defined as a soft metal with high aﬃnity for
soft non-metal sulfur.26,27 Therefore, during blood circulation,
unintended deactivation of cisplatin may be caused by bio-
molecules containing thiol groups, such as cysteine and
human serum albumin.26–29 Some studies have demonstrated
that about 65–98% of Pt becomes bound to blood proteins one
day after cisplatin administration.28,29 Therefore, only a small
number of Pt(II)-based drugs can maintain their activity during
blood circulation and enter cancer cells mainly by passive
diﬀusion and/or by the copper transporter CTR1 (Fig. 2).3,26–30
The relatively low concentration of chloride in the cells facili-
tates the replacement of chloro ligands in Pt(II)-based drugs by
water, resulting in the mono-aquated Pt complex. The aquated
form is reactive to guanine and adenine in DNA. The resulting
intra- and inter-strand crosslinks distort the DNA duplex,
causing the apoptosis of cancer cells.3,26,27,31,32 However, in
some cases, the eﬃcacy of cisplatin may be limited by inherent
or acquired cisplatin resistance. The major mechanisms of
resistance can be classified into four categories: inactivation
by increased thiol-containing molecules, an increased DNA-
repair capacity, reduced uptake/enhanced eﬄux, and failure of
apoptotic pathways.3,26,30,31 Oxaliplatin (Fig. 1B) is a successful
alternative drug to overcome the limitations of cisplatin in the
treatment of cisplatin-resistant tumors. It has been reported
that the bulky diaminocyclohexane (DACH) ligand of oxalipla-
tin contributes to overcoming the drug resistance arising from
the mechanism of DNA mismatch repair recognition.3,30,33–35
In addition, cis-ammine(2-methylpyridine)dichloroplatinum(II)
(ZD0473) is another alternative drug candidate for overcoming
the cisplatin resistance induced by increased thiol-containing
cellular components (Fig. 1C). It has been proposed that the
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steric hindrance of ZD0473 prevents the approach of gluta-
thione (GSH). This strategy is not only able to maintain the
cytotoxic ability of Pt-based drugs, but is also able to reduce
deactivation by GSH.3,30,35 Another strategy to avoid cisplatin
resistance involves BBR3005, a multinuclear Pt(II)-based drug
(Fig. 1D). By inducing the irreversible B → Z transition in DNA
structures with long range intra- and inter-strand crosslinks,
multinuclear Pt(II)-based drugs prevent the detection of
damaged DNA by DNA damage-recognition proteins.35,36
Although a Pt(IV) complex was firstly identified together
with cisplatin in Rosenberg’s original work, its potential as an
anticancer drug has been recently recognized.26,32,37–39 Pt(IV)-
based drugs have a d6 octahedral geometry, generally believed
to be less reactive towards nucleophiles than Pt(II) complexes.
The axial ligands of Pt(IV) complexes have an important role in
making them relatively inert compared to the Pt(II) complexes.
The enhanced stability of Pt(IV) complexes is expected to
improve the stability of Pt-based drugs and increase their half-
life in the blood stream. In addition, the axial ligands ideally
can exhibit functional moieties that can be modified by target-
ing ligands to achieve active targeting, by other components in
order to overcome drug resistance, and by polymers for deve-
loping drug-delivery systems.32,37–39 The Pt(IV)-based drugs
undergo reduction to Pt(II) inside the cells, which eliminates
the two axial ligands of the octahedral Pt(IV)-based drug
(Fig. 2). The reactive Pt(II) analogs produced by the reduction
process exert the anticancer activity.26,32,37–39 Because of the
reactivity change before and after reduction, Pt(IV)-based drugs
are generally considered to be prodrugs.38 However, only a few
Pt(IV) complexes such as satraplatin (Fig. 1E) have been
involved in significant clinical trials, despite the rational
design of Pt(IV) prodrugs.37–39 In order to proceed to further
clinical practice, it is highly necessary to establish new syn-
thetic chemistry, optimize the kinetics of reduction, and
develop well-designed drug delivery systems.38,39
3. Physical encapsulation of Pt(II)
3.1. Traditional techniques
Traditional strategies for the delivery of Pt-based drugs are
based on physical encapsulation—an approach that has been
widely used in general drug delivery systems. These strategies
have the merits of easy and simple procedures for loading
drugs into the nanoparticles; however, they have been lamen-
ted for their low loading stability which causes the unintended
loss of drugs during blood circulation.40 Several techniques
have been developed for the potential use of encapsulation
methods.41–44 Desolvation is one of the most frequently used
strategies for fabricating nanoparticles. Protein nanoparticles
developed by the desolvation method represent ideal candi-
dates for the delivery of anticancer drugs because of their
biodegradable, less immunogenic, and non-toxic character-
istics.41,42 Very recently, a folic acid-conjugated gelatin nano-
particle (Cis-GN-FA) for cisplatin delivery has been developed
through a double desolvation method.45 In the case of folate-
negative A549 lung cancer cells, it was diﬃcult to distinguish
Cis-GN-FA from Cis-GNs. In contrast, the Cis-GN-FA nano-
particles show a significant decrease of the half maximal
inhibitory concentration (IC50) (8.3 mM) in folate receptor-
active HeLa cells, compared to Cis-GNs (15.1 mM) and cispla-
tin (40.2 mM), implying that further in vivo investigations of
Cis-GN-FA are needed.
The emulsion technique is another common encapsulation
method, which is based on the compatibility between a drug
and a matrix.41–43 In the case of poorly soluble and lipophilic
Fig. 2 Schematic diagram of the cytotoxic pathway of Pt-based drugs. Cisplatin is a representative. After entering the cell by copper transferase
receptor (CTR1) or passive diﬀusion, cisplatin was activated by replacing a chloride ion with water molecules in low concentration of chloride ions
(aquation). The aquated cisplatin binds to DNA. Distortion of DNA activates the programmed cell death. Pt(IV) prodrugs were activated by reduction
of two axial positions, resulting in the release of active Pt(II) complexes. After this, the mechanism is similar to cisplatin.
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drugs, the oil-in-water (o/w) single emulsion method has been
utilized for physical encapsulation of the drugs. In addition,
double emulsion techniques like water-in-oil-in-water (w/o/w),
solid-in-oil-in-water (s/o/w), water-in-oil-in-oil (w/o/o), and
solid-in-oil-in-oil (s/o/o) have been employed for compounds
with high solubility in water, including proteins, peptides, and
drugs like cisplatin.41–43 These common techniques have been
frequently applied in cisplatin-delivery systems. A study illus-
trating the development of cisplatin-encapsulated poly(lactic-
co-glycolic acid) (PLGA) nanoparticles (NP) by the double emul-
sion technique has also been reported recently.46 The deve-
loped PLGA NPs showed a sustained cisplatin release, with a
cumulative release of 50% over 3 weeks, highlighting the
potential of this system for avoiding multiple administrations
of cisplatin in cancer treatment. In another study, cisplatin
was emulsified into methoxy poly(ethylene glycol)-block-poly-
(lactic-co-glycolic acid)-block-poly(L-lysine) (mPEG-b-PLGA-b-
PLL) nanoparticles (CDDP-NPs) using the w/o/w double emul-
sion method, followed by conjugation of an epidermal growth
factor (EGF) ligand to the CDDP-NPs via EDC/NHS chemistry.47
The developed CDDP-NP-EGF not only showed sustained drug
release profiles in vitro, but also showed lower nephrotoxicity
and improved anticancer eﬀects on ovarian carcinoma in vivo.
This simple and universal emulsion technique has been used
to develop novel and complex delivery systems as well. In 2014,
Chen et al. reported an interesting nanocarrier system which
releases both Pt(II)-based drugs and O2 in response to the local
H2O2 concentration typical of the tumor environment
(Fig. 3).48 In this system, Pt(II)-based drugs ([PtLCl]Cl) and
catalase were incorporated into the aqueous core of PLGA
nanoparticles via the double emulsion method. The catalase
generated O2 from intracellular H2O2, resulting in the rupture
of the nanoparticle shell by the increased internal pressure. In
addition, the Pt(II)-based drug and O2 exhibited anticancer
eﬀects and the ability to overcome hypoxia-induced multidrug
resistance (MDR),49 respectively. Although further investi-
gations are necessary, this novel system could enhance the
anticancer eﬃciency of cisplatin at the in vitro level.
Nanoprecipitation, based on the interfacial deposition, is a
convenient and commonly used method for the preparation of
polymeric nanoparticles.43,44 Recently, a biodegradable multi-
functional nanoparticle (MNP) system for co-delivery of cispla-
tin and genes has been developed. Cisplatin-loaded poly(lactic
acid) (PLA) nanoparticles were prepared via nanoprecipitation,
and the surface was then coated with chitosan for electrostatic
complexation with genes.50 The MNP is thus composed of a
PLA inner core loaded with cisplatin and a cationic chitosan
(CS) outer layer with P62 siRNA (siP62) and/or β5-expressing
plasmid DNA (pβ5) (Fig. 4). The co-delivered genes could
knock down P62 and restore β5 expression, resulting in a
Fig. 3 Schematic illustration of H2O2-responsive PLGA nanoparticles containing Pt(II) drugs and O2-generating catalase and the mechanism of drug
release by H2O2 (reproduced from ref. 48 with permission from the Royal Society of Chemistry).
Review Biomaterials Science
1006 | Biomater. Sci., 2015, 3, 1002–1017 This journal is © The Royal Society of Chemistry 2015
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
A
pr
il 
20
15
. D
ow
nl
oa
de
d 
on
 7
/1
7/
20
19
 7
:5
4:
18
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
remarkable reduction in the IC50 value of cisplatin in cisplatin-
resistant ovarian cancer cells. This simple co-delivery system
has thus shown a potential ability to overcome the problems
arising in the treatment of cisplatin-resistant tumors. Huang
et al. have recently reported another co-delivery system capable
of changing the tumor microenvironment for enhanced anti-
cancer eﬀects.51 To improve the encapsulation eﬃciency, cis-
platin was coated with dioleoyl phosphatidic acid (DOPA). The
DOPA-coated cisplatin cores facilitated the co-encapsulation of
cisplatin and rapamycin, an mTOR inhibitor with antiangio-
genic properties, into the PLGA via nanoprecipitation. The
developed PLGA nanoparticles not only suppressed the tumor
growth, but also altered the microenvironment of the tumor,
inhibiting angiogenesis, reducing tumor-associated fibroblasts
and collagen expression, and improving EPR eﬀects of the
nanoparticles in tumors. These findings have raised the expec-
tations in the development of novel theranostic systems based
on multifunctional nanoparticles such as quantum dots,
superparamagnetic iron oxide nanoparticles, gold nanoparti-
cles, and so on.
3.2. Micelles
Polymeric micelles are nanoscopic core–shell structures
formed by amphiphilic block copolymers. They are generated
when the hydrophobic portions of the polymers are driven to
the interior of the structure, while the hydrophilic portions are
exposed to the aqueous environment. These micelles have
been widely used for general drug-delivery systems, as the
hydrophobic interior has the capacity to hold drugs that are
poorly soluble in aqueous solution.12,20,52,53 However, as far as
cisplatin delivery is concerned, the hydrophilic nature of cis-
platin makes it diﬃcult to obtain cisplatin-encapsulated
micelles. The successful encapsulation of a hydrophobic Pt(II)
compound, cis-(cha)2Pt(NO3)2, into the amphiphilic cyclotri-
phosphazene [NP(MPEG750) (GlyPheLeu)2Et]3 (CP750) to form
the micelle was recently reported.54 Compared to free cis-
(cha)2Pt(NO3)2, the micelle not only exhibited prolonged blood
circulation and large systemic exposure (AUC), but also
showed excellent tumor accumulation and low acute toxicity.
In particular, the micelle showed significant anticancer eﬀects
on the SNU638 cell line, a drug-resistant stomach carcinoma
cell.
4. Physical encapsulation of Pt(IV)
The fundamental principles for physical encapsulation of a
Pt(IV) prodrug in a nanoparticle are in line with those of Pt(II)-
based drugs. The primary diﬀerence is that a Pt(IV) prodrug
has two more ligands at its axial positions, and these
additional ligands can be useful to encapsulate the Pt(IV)-
based drug into the nanoparticle. For instance, a Pt(IV)-based
Fig. 4 Schematic diagram of the preparation of siRNA/pDNA-CS-CDDP-PLNP. CDDP-PLNP was prepared by the nanoprecipitation method
(Step 1), which was subsequently coated with CS layers (Step 2). The siRNA/pDNA-CS-CDDP-PLNP complex was formed via electrostatic interactions
between siRNA/pDNA and CS-CDDP-PLNP (Step 3) (reproduced from ref. 50 with permission from the American Chemical Society).
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drug can be easily encapsulated into the hydrophobic parts of
a nanoparticle if its axial ligands are modified by hydrophobic
groups.55 Recently, Farokhzad and Lippard’s group reported
the development of targeted-delivery systems with reduced
side eﬀects by using simple nanoprecipitation and hydro-
phobic Pt(IV) prodrugs.56,57 Hydrophobic aliphatic chains at
the axial position of Pt(IV) drugs helped in the eﬃcient encap-
sulation of the drug into the hydrophobic core of methoxy
poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) (PEG-b-
PLGA) nanoparticles via nanoprecipitation.55–57 In addition,
the inertness of Pt(IV) is expected to mitigate side eﬀects, like
nephrotoxicity, compared to Pt(II)-based drugs, because the
protection of the axial position of the drug can reduce the reac-
tivity of Pt towards biomolecules. In particular, the conju-
gation of the cyclic arginine-glycine-aspartate (cRGD) ligand or
the prostate-specific membrane antigen (PSMA) aptamer onto
the nanocarriers facilitated the active targeting of drugs to the
corresponding receptor on a tumor. In fact, cRGD-tethered
and hydrophobic Pt(IV) drug-encapsulated mPEG-b-PLGA
nanoparticles exhibited favorable anticancer eﬀects on αvβ3
integrin-overexpressed cancer cell lines in vitro.56 Furthermore,
PSMA-tethered and hydrophobic Pt(IV) drug-encapsulated
mPEG-b-PLGA nanoparticles showed significant anticancer
eﬀects on PSMA-overexpressed LNCaP cells in xenograft mouse
models, as well as a remarkable pharmacokinetic index
without nephrotoxicity and changes in body weight.57 These
basic principles have been extended to the development of
several co-delivery systems. In 2013, Farokhzad and Walker’s
group modified the procedures for preparing mPEG-b-PLGA
nanoparticles containing hydrophobic Pt(IV) prodrugs, in
order to simultaneously load siRNA.58 By adding a cationic
lipid-like molecule (G0-C14) in the double emulsion process,
they were able to obtain a nanoparticle whose structure
involves an aqueous core, a cationic and hydrophobic layer
formed by G0-C14 and PLGA, and a hydrophilic outer shell
composed of PEG. The G0-C14 has a pivotal role in the fabrica-
tion of the nanoparticle, because it provides flexible hydro-
phobic tails for self-assembly into the PLGA matrix, as well as
eﬃcient binding with the negatively-charged siRNA. These for-
mulations enable the fabrication of nanoparticles with a dense
structure, resulting in a sustained release of siRNA and Pt(IV)
drug payloads. In addition, the nanoparticles exhibit a signifi-
cant inhibition of tumor growth in vivo owing to the synergy of
antitumor eﬀects by Pt(IV) prodrugs and sensitization by
siREV1/siREV3L. Moreover, hydrophobicity can be introduced
by conjugating hydrophobic anticancer drugs at the axial posi-
tion of a Pt(IV) prodrug. Zhang’s group reported the synthesis
of lipid–polymer hybrid nanoparticles for the delivery of a
drug conjugate composed of a hydrophilic Pt(IV) prodrug and
the hydrophobic paclitaxel (Ptxl) (Fig. 5).59 The drug conjugate
can be loaded into the lipid–polymer hybrid nanoparticles via
nanoprecipitation. The loading of a drug conjugate system
within a polymeric nanocarrier is expected not only to provide
a route for improving loading of Pt-based drugs, but also to
prevent limitations in anticancer eﬀects arising from the vari-
ation of pharmacokinetics and biodistribution of diﬀerent
drugs in cocktail chemotherapy strategies.
5. Conjugation of Pt(II)
5.1. Pt(II)-conjugated micelles via labile leaving ligands
Pt(II)-based drugs typically consist of two permanently bound
ligands, usually amines, and two labile leaving ligands like
chlorides or carboxylate functional groups. The conjugation of
Pt(II)-based drugs to a polymeric carrier has been accom-
plished either via leaving ligands or via permanent ligands.
Conjugation via leaving ligands is widely used, as inspired by
carboplatin which carries carboxylate as a leaving ligand. It is
relatively straightforward to obtain polymer–Pt(II) conjugates
Fig. 5 (A) Synthesis of a drug conjugate composed of Ptxl and Pt(IV) prodrugs. (B) Schematic illustration of a Ptxl–Pt(IV) conjugate loaded polymeric
nanoparticles. (C) Dynamic light scattering (DLS) analysis and (D) scanning electron microscopy (SEM) images of the nanoparticles containing a
Ptxl–Pt(IV) conjugate (reproduced from ref. 59 with permission from the Royal Society of Chemistry).
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structurally similar to carboplatin by conjugating a Pt(II)-based
drug to a polymer having pendant carboxyl functionalities.10,37
In addition, monofunctional conjugation, bifunctional conju-
gation, and/or crosslinking of polymer chains can be obtained
upon coordinating a Pt(II)-based drug to a polymer containing
carboxylate groups.60,61
There have been several notable reports on the development
and evaluation of micelles incorporating Pt(II)-based drugs via
coordination between carboxylate functional groups of a block
copolymer and leaving ligands of the drugs.62–77 For example,
Sengupta et al. developed self-assembled micelles by com-
plexation via mono- and di-carboxylate linkages between poly-
(ethylene glycol)-poly(isobutylene-alt-maleic anhydride)
(PEG-PIMA) and diaquated cisplatin. The nano-sized particles
exhibited superior antitumor eﬃciency compared with free cis-
platin, owing to the EPR eﬀect.65 Moreover, tumor-targeted
micelles for the delivery of Pt(II)-based drugs against specific
receptor-positive cell lines have been frequently reported.66–68
For instance, Zhang and Yu’s group developed micelles fabri-
cated from folate-conjugated poly(ethylene glycol)-graft-
α,β-poly [(N-amino acidyl)-aspartamide] (FA-PEG-g-PAAsp) and
Pt(II)-based drugs, and demonstrated their favorable antitumor
eﬀects.68 In addition, as a representative example of co-deliv-
ery, we discuss the polymeric co-delivery system inspired by
the GEMOX chemotherapy regimen, i.e., co-administration of
gemcitabine and oxaliplatin.69 Gemcitabine is a nucleoside
derivative of deoxycytidine and is involved in the repair and
synthesis of DNA. It has been demonstrated that gemcitabine
is eﬀective on non-small cell lung cancer, pancreatic cancer,
bladder cancer, colon, and breast cancer.69,70 However, the low
stability of gemcitabine in vivo requires the administration of
high doses, which causes adverse side eﬀects. To overcome
these problems, Jing’s group developed micelles containing
oxaliplatin–polymer (P(Pt)) and gemcitabine–polymer (P(Gem))
conjugates.69 Due to the identical polymer backbones, poly-
(ethylene glycol)-block-poly(L-lactide-co-2-methyl-2-carboxyl-pro-
pylene carbonate) (mPEG-b-P(LA-co-MCC)), P(Pt) and P(Gem)
could co-assemble to form hybrid micelles with controlled
gemcitabine/oxaliplatin ratios. The co-assembled micelle
exhibited enhanced drug accumulation in the tumor site,
resulting in the eﬃcient inhibition of tumor growth compared
to single-drug administration and co-administration.
Traditionally, poly(aspartic acid), poly(glutamic acid), and
poly(methacrylic acid) were employed for generating polymer–
Pt(II) complexes. However, these common polymers coordinate
to the Pt(II)-based drugs in a non-specific geometry, resulting
in uncontrolled crosslinking and mixed configurations such as
monodentate or bidentate coordination.71,72 Therefore, Sten-
zel’s group aimed to develop a structurally defined Pt(II)-based
drug carrier by investigating the eﬀects of polymer architec-
tures or by using neighboring carboxylate functional
groups.71,72 Their analysis confirmed that polymers that form
7-membered rings with Pt enhance the solubility of polymer–
Pt(II) conjugates, while those that form 11-membered rings led
to low solubility due to inter-polymer crosslinking.71 In
addition, it was revealed that statistical copolymers showed
complete drug release, in contrast to block copolymers that
released around 40% of a Pt-based drug.71 However, it was
found that the cytotoxicity was not closely related to the drug
release, but was related to the cellular uptake.71 Stenzel’s
group also tried to develop polymeric micelles with defined
geometry by using bidentate carboxylate ligands.72 They
demonstrated that the formation of 6-membered rings with Pt
provided stability to the complex, and that drug release was
increasingly more eﬀective as the hydrophobic block with cis-
platin became shorter.72
A major disadvantage of micelles is their instability during
blood circulation, due to the unintended contact with blood
components and the dilution to below critical micellar concen-
tration (CMC). Covalent crosslinking has attracted significant
interest as one of the options for improving the stability of
micelles.73,74 This methodology has also been applied to the
delivery of Pt(II)-based drugs using micelles.71,75–77 For
example, Stenzel’s group used 2,2′-(ethylenedioxy)bis(ethyl-
amine) as a crosslinker of micelles, not only to stabilize the
micelles, but also to improve the cytotoxic eﬀects of cisplatin
by inducing eﬃcient cellular uptake.71 However, permanently
stable crosslinkers have a potential risk to limit the drug
release and interrupt the renal clearance of the polymeric car-
riers.76,77 Therefore, Huynh et al. utilized an acid-degradable
acetal crosslinker to prepare cisplatin-conjugated micelles
composed of poly(oligo(ethylene glycol) methylether methacry-
late)-block-poly(N-hydroxysuccinic methacrylate)-block-poly(1,1-
di-tert-butyl 3-(2-(methacryloyloxy)ethyl) butane-1,1,3-tricarbox-
ylate) (POEGMEMA-b-PNHSMA-b-PMAETC).76 POEGMEMA
occupies the hydrophilic shell, and the PMAETC block is
responsible for the complex formation with cisplatin. The
hydroxyl succinimide groups in the PNHSMA block react with
the diamine of the acetal crosslinker to produce the cross-
linked micelle. Qiao’s group employed the same strategy to
develop pH-sensitive micelles for cisplatin delivery (Fig. 6).77
The linear-brush diblock copolymer contains anhydride groups
and grafted PEG, which self-assemble into the micelle. Sub-
sequently, the micelle was crosslinked by the reaction between
anhydride groups of diblock copolymers and diamine of the
acetal crosslinkers. These two types of pH-sensitive micelles
showed a faster drug release under acidic conditions and a
higher cellular uptake compared to free drugs and uncross-
linked micelles, thus resulting in enhanced anticancer eﬀects.
5.2. Metallosomes
Besides the regular spherical micelles, amphiphilic block
copolymers can self-assemble into diverse ordered structures,
such as worm-like micelles, multilayer structures, and poly-
mersomes. It has been reported that the structure of amphi-
philic block copolymers in aqueous solutions is determined by
the ratio of hydrophilic block to total polymer mass. The poly-
mersome can be defined as a polymer-based liposome formed
from synthetic polymers, rather than lipids or natural poly-
mers, via supramolecular assembly.78–84 Polymersomes are
typically hollow spheres consisting of an aqueous core and a
polymeric bilayer shell. The shells are composed of three
Biomaterials Science Review
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parts: an inner hydrophilic region, a middle hydrophobic part,
and an outer hydrophilic part. The polymersomes have
attracted considerable attention in the field of drug-delivery
systems owing to their superior properties. First, they can
encapsulate hydrophilic agents in their aqueous core and inte-
grate hydrophobic drugs within the hydrophobic regions of
the shells. In addition, the dense structure of the hollow shell
not only provides structural stability to the polymersomes, but
also reduces the permeability of the inner components. This
reduced permeability can enhance the drug-loading eﬃciency
and reduce the leakage of the drugs during blood circulation.
Furthermore, the diverse synthetic routes for block copolymers
provide an easy way to tune the properties of the polymer-
somes. In 2012, Kataoka’s group reported a polymersome with
a remarkable structure for the delivery of Pt(II)-based drugs
(Fig. 7).85 In contrast with general polymersomes formed by
hydrophobic or electrostatic interactions, they developed
metallosomes by exploiting the coordination of Pt(II)-based
drugs. The complex between (1,2-diaminocyclohexane)plati-
num(II) (DACHPt) (Fig. 1F) and the carboxylic functional
groups of Y-shaped block copolymer (PEGasus-b-PLGA-Chole)
composed of ω-cholesteroyl-poly(L-glutamic acid) and two-
armed poly(ethylene glycol) triggered the metallosome for-
mation. The metallosome showed sustained release of active
Pt(II)-based drugs and eﬀective suppression of tumor growth.
In addition, by showing the feasibility of loading water-soluble
fluorescent molecules into the metallosomes, this strategy
shows potential applications to the co-delivery of other thera-
peutic agents.
5.3. Micelles crosslinked by Pt(II)-based drugs
The ability of Pt(II)-based drugs to coordinate to two carboxylic
groups provides a route to crosslink nanoparticles composed
of polymers with carboxylic functional groups.62–64,66,67,86–89
That is, conjugation via leaving ligands of Pt(II)-based drugs
can perform an important role in stabilizing the nanoparticles,
as well as in conjugating the drug to the carrier.60–64,66,67,86–89
Song et al. developed a polymeric micelle using the biocompa-
tible triblock copolymer, methoxy poly(ethylene glycol)-block-
poly(L-glutamic acid)-block-poly(L-phenylalanine) (mPEG-b-P-
(Glu)-b-P(Phe)), for the co-delivery of Ptxl and cisplatin.87 The
triblock copolymer was rationally designed: the hydrophobic
P(Phe) block is responsible for the Ptxl encapsulation, the
P(Glu) segment performs the conjugation of cisplatin and the
crosslinking of the micelles, and mPEG in the outer corona
can prolong the blood circulation time. It was demonstrated
that the crosslinks created via coordination of cisplatin con-
tributed to alleviate the initial burst release of Ptxl from the
micelles. In addition, the micelles showed an enhanced anti-
tumor eﬃcacy with reduced side eﬀects in vivo. Kim et al.
reported an interesting strategy to form micelles containing
cisplatin and photodynamic agents.88 They employed cisplatin
as a crosslinker among components containing carboxylic
functional groups, such as phthalocyanine (DPc) and poly-
(ethylene glycol)-block-poly(L-aspartic acid) (PEG-b-PLAn). The
developed polymer–metal complex micelles (PMCM) formed
Fig. 6 Schematic diagram of the preparation of a Pt(II)-loaded poly-
meric vesicle with an acid-degradable crosslinker (reproduced from ref.
77 with permission from the Royal Society of Chemistry).
Fig. 7 Schematic diagram of the formation of metallosomes via self-assembly of the polymer–metal complex. A Pt in the DACHPt was located
between two polymer chains by coordinating with carboxylates in the poly(L-glutamic acid) (PLGA) segment (reproduced from ref. 85 with per-
mission from the American Chemical Society).
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unimodal nano-sized particles that exhibited high stability in
buﬀer solution. Although the generation of singlet oxygen was
confirmed, the synergistic eﬀects of cisplatin and singlet oxygen
still need to be investigated. Koseva’s group exploited the cross-
linking ability of cisplatin to develop a reversible PEGylated
strategy.89 A residual leaving ligand of PEG-cisplatin was used as
a glue between PEG and the carboxylic functional groups in
star-type block copolymers. This strategy, capable of simul-
taneously loading Pt(II)-based drugs, is expected to control the
pharmacological behavior of the drugs and the nanocarriers.
5.4. Pt(II)-conjugated nanoparticles via permanently bound
ligands
Chemical conjugation via permanently bound ligands has
been occasionally employed to obtain polymer–Pt(II) conju-
gates because of the diﬃculty in modification of permanent
ligands.10,37 In particular, the biodegradability of Pt(II)-conju-
gated nanoparticles is important in the case of conjugation via
permanently bound ligands. According to various studies, it
has been hypothesized that the stable macromolecular struc-
tures of polymer–Pt(II) conjugates formed via permanent
ligands suppress the chemotherapeutic eﬃciency of the Pt(II)-
based drugs.12 Therefore, many research studies have
employed acid-degradable linkers for developing polymer–
Pt(II) conjugates via permanently bound ligands.
In the process of developing and exploiting polymer-caged
nanobins (PCNs) formed by crosslinking polymers which are
incorporated into bare liposomes, Lee et al. evaluated the
ability of PCNs to load and deliver two types of cytotoxic
agents, doxorubicin and Pt(II)-based drugs (Fig. 8A).90–92 The
doxorubicin could be loaded into the liposomes by hydro-
phobic interactions. By conjugating the pH-sensitive C6-amine
moiety of a cisplatin derivative (PtII(NH3)2(N-AcLys)) (Fig. 8B)
to the carboxylic acid in the polymeric shell composed of
cholesterol-terminated poly(acrylic acid), the developed PCN
also contains a cisplatin derivative in the shell.92 This co-deliv-
ery system exhibited higher synergistic cytotoxicity than the
combination of either the free drugs or the separately nano-
packaged drugs. These results clearly demonstrate that the
PCN platform can oﬀer new means for building synergy into
combination chemotherapy. Binauld et al. reported a strategy
to introduce acid-degradable linkages between the polymer
backbone and the permanently bound amine ligands of Pt(II)-
based drugs (Fig. 9).93 Their methodology exploited the high
stability of the bonds between Pt and permanently bound
ligands to enhance the pH responsiveness. The micelle formed
by self-assembly of pH-sensitive polymer–Pt(II) conjugates
showed an acid-accelerated drug release behavior.
6. Conjugation of Pt(IV)
6.1. Traditional strategies with Pt(IV)–polymer conjugates
The axial ligands of Pt(IV) complexes provide the drugs an
opportunity to be encapsulated eﬃciently into the nanoparti-
Fig. 8 (A) Synthesis of Pt(II)-conjugated and doxorubicin (DXR)-loaded Polymer-Caged Nanobins (PCNs). The DXR-loaded liposomes were coated
with polymers which could act as a reservoir for Pt(II) drugs. Polymer shells provide structural stability to liposomes and controlled release of DXR
and Pt(II) drugs. (B) Synthetic scheme of [PtII(NH3)2(Nα-AcLys)] (reproduced from ref. 92 with permission from the American Chemical Society).
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cles via traditional and simple methods.32,37–39,55 In addition,
combination chemotherapy has emerged as a possible solu-
tion for drug resistance, due to its ability to interrupt one or
more cellular mechanisms related to apoptosis and survi-
val.94,95 In particular, a prodrug comprised of Pt(IV)-based
drugs and polymers can contribute to eﬀectively encapsulate
other anticancer agents, as well as Pt(IV)-based drugs, into the
nanoparticles developed by nanoprecipitation. Mi et al. deve-
loped a strategy for targeted co-delivery of a Pt(IV) prodrug and
docetaxel.94 D-α-Tocopheryl-co-poly(ethylene glycol) 1000 succi-
nate (TPGS), which has a water-soluble amphiphilic structure,
was employed to incorporate a Pt(IV) prodrug. TPGS-COOH, the
TPGS-Pt(IV) prodrug, and PLA-TPGS were nanoprecipitated
with docetaxel to form the nanoparticles (HTCP-NP) for combi-
nation chemotherapy. Herceptin, which targets the HUR-2
receptor overexpressed in breast cancer, could react with car-
boxylic groups exposed on the HTCP-NP surface. This
approach can be applied to the targeted co-delivery of various
hydrophilic and hydrophobic drugs. Kolishetti et al. illustrated
a platform technology for combination chemotherapy invol-
ving a Pt(IV)–polymer conjugate and the microfluidic nanopre-
cipitation method.95 The Pt(IV)-based drugs were tethered to
the pendant hydroxyl group of a hydrophobic poly(lactide)
derivative, followed by the formation of nanoparticles with
docetaxel and the PEG-b-PLGA block copolymer through the
microfluidic nanoprecipitation method. This platform techno-
logy provides excellent drug encapsulation eﬃciency and
reproducibility. In addition, the introduction of the A10
aptamer supplemented the nanoparticles with the ability to
target PSMA-overexpressed prostate cancer cells. PSMA-tar-
geted nanoparticles encapsulating a Pt(IV) prodrug and doce-
taxel showed enhanced cytotoxicity compared to nanoparticles
containing the individual single drugs. This approach showed
significant potential for providing conventional methods
capable of developing uniform nanoparticles for a targeted co-
delivery system incorporating Pt-based drugs.
6.2. Pt(IV)-conjugated micelles
In addition to providing hydrophobicity to Pt-based drugs, the
axial ligands of Pt(IV) complexes can enable the conjugation of
the drug directly with the nanoparticles,32,37–39 which would
allow the successful and eﬃcient incorporation of Pt-based
drugs into the micelles. Stenzel’s group demonstrated the
ability of a polymeric micelle containing oxoplatin and folate
ligands to deliver the Pt(IV)-based drug into folate receptor-
overexpressed ovarian cancer cells (Fig. 10).96 In this system,
oxoplatin was successfully loaded into the micelles via an ester
linkage between the carboxyl group of hydrophobic segments
of the amphiphilic block copolymer and the hydroxyl group of
oxoplatin. The micelle was designed to release cisplatin by
hydrolysis of the ester linkage and subsequent reduction of
oxoplatin in the cytosol. Folate ligands were introduced to the
ends of hydrophilic segments through the interaction between
phenylboronic acid and dopamine. This simple chemistry
enables easy control of the amount of folate ligands on the
micelle, which aﬀects the IC50 value of oxoplatin. In addition,
the micellar core was crosslinked to provide structural stability
to the micelle, allowing the drugs to enter the cell eﬃciently.
Although it has been reported that Pt(IV)-based drugs are
activated by the cellular environments, the drug eﬃcacy can be
limited due to the dependency of the drug release on indirect
processes such as acid hydrolysis and/or reduction.97–100 Fol-
lowing a high demand for systems capable of releasing Pt(II)
complexes directly, Sadler and co-workers reported a photosen-
sitive Pt(IV)–diazido complex which is converted to Pt(II)
species under mild UV irradiation.97,98 The UV irradiation
breaks the Pt–N3 bond, resulting in the release of the Pt(II)
complex.97,98 Based on the photosensitive characteristics of
Fig. 9 Preparation of the hydrazone copolymer–Pt(II) complex and illustration of micelles through self-assembly of polymer–drug conjugates. The
hydrazone bond was cleavable under acidic conditions, resulting in the release of Pt(II) (reproduced from ref. 93 with permission from the American
Chemical Society).
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the Pt(IV)–diazido complex, polymeric micelles which showed
light-responsive release of active Pt(II)-based drugs have been
developed by conjugating the Pt(IV)–diazido complex to poly-
mers via an ester or amide linkage.99,100 The micelles showed
rapid release of Pt(II) species under UV irradiation, whereas they
were stable under dark conditions. These micelles also exhibi-
ted enhanced cytotoxicity under UV irradiation, as well as inhi-
bition of tumor growth in vivo, with reduced side eﬀects.
Li et al. reported multi-stage Pt(IV) prodrug-delivery systems
mimicking the common polymeric gene-delivery systems.101
The mono-carboxylated Pt(IV) complexes were conjugated with
cationic dendrimers, and the as-synthesized cationic prodrugs
formed polyplex micelles with the anionic diblock copolymer.
According to the design, the cationic Pt(IV)–dendrimer conju-
gates are dissociated from the polyplex micelles due to the
charge conversion of anionic segments of the diblock copoly-
mer at tumoral acidic pH (∼6.0). Subsequently, cisplatin can
be released from Pt(IV)–dendrimer conjugates by the reductive
environment in the cytosol. The polyplex micelles showed an
ability for deep penetration in tumor tissue and enhanced
anticancer eﬀects compared to cisplatin.
6.3. Pt(IV)-conjugated micelles for co-delivery
Approaches involving drug-conjugated micelles have attracted
considerable attention for the development of co-delivery
systems. Unlike the physical encapsulation strategies, conju-
gated micelle systems provide Pt(IV)-based drugs and other
combinatorial drugs with structural stability and ability of con-
trolled release. Xiao et al. investigated micelles for co-delivery
of daunomycin (DRB) and oxaliplatin.102 The DRB and the
prodrug of oxaliplatin were attached to a biodegradable amphi-
philic polymer, and the resulting two types of drug–polymer
conjugates were co-assembled into the micelle. The diﬀerent
linkages between each drug and the polymer have a diﬀerent
eﬀect on the drug release. The polymer–Pt(IV) conjugate exhibi-
ted rapid release of the Pt(II) complex obtained by reduction,
while the polymer–DRB conjugate showed sustained release
due to acid hydrolysis. In addition, the micelles showed
reduced systemic toxicity and synergistic eﬀects both in vivo
and in vitro.
The two axial ligands of Pt(IV)-based drugs can be used for
incorporating additional functionalities. For example, if one
Fig. 10 Synthesis of Pt(IV) prodrug attached poly(oligo(ethylene glycol) methyl ether methacrylate)-b-poly(methacrylic acid) block copolymers
(p(OMGMEMA)-b-p(MMA)) with a pendant dopamine group. After self-assembling, the folate ligands were introduced on the surface of micelles
via dopamine–phenylboronic ester interaction and the cores of micelles were crosslinked for structural stability (reproduced from ref. 96 with
permission from the American Chemical Society).
Biomaterials Science Review
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ligand contains agents for combination therapy and the other
is conjugated with the nanocarriers, a co-delivery system with
synergistic eﬀects, enhanced stability, and passive targeting
ability can be developed. Inspired by mitaplatin (Fig. 1G),
which contains two dichloroacetate (DCA) ligands in the axial
positions of cisplatin, Xiao et al. developed micelles containing
a Pt(IV) prodrug with a DCA ligand and a carboxylic group in
its axial positions.103 DCA is a mitochondria-targeting small
molecule which inhibits glycolysis, enhancing the mitochon-
drial apoptosis in cancer and suppressing tumor growth. The
carboxylic group at the axial positions of a DCA–Pt(IV) conju-
gate was linked to an amphiphilic biodegradable block copoly-
mer (methoxy poly(ethylene glycol)-block-poly(caprolactone)-
block-poly(L-lysine), mPEG-b-PCL-b-PLL) for the formation of
micelles. The enhanced anticancer eﬀects of this polymeric
delivery system might be attributed to the individual pharma-
cological mechanism of each anticancer drug. Qi et al.
described a similar Pt(IV) prodrug delivery system.104 Camphor
anhydride is a derivative of camphor that can down-regulate
the intracellular levels of Bcl-2 expression, enabling to over-
come the resistance to cisplatin. Conjugation of camphor
anhydride with one of the axial positions of Pt(IV) prodrugs
generated camplatin (Fig. 1H) and the other axial position was
further linked to biocompatible mPEG-b-PCL-b-PLL. The as-
prepared polymer–camplatin conjugate could self-assemble
into micelles. The micelles exhibited enhanced cytotoxicity
on both cisplatin-sensitive and cisplatin-resistant cell lines
compared to free cisplatin, because of the synergistic eﬀects
of the cytotoxic Pt-based drug and the camphoric acid
chemosensitizer.
6.4. Micelles crosslinked by Pt(IV) prodrugs
In addition to providing functional moieties that can be modi-
fied with other therapeutic agents, the two axial ligands can
act as crosslinkers among polymers, leading to the formation
and stabilization of the micelle structures. By taking advantage
of this characteristic, Aryal et al. reported a pH-responsive
delivery system, with the Pt(IV) prodrug employed as both an
anticancer agent and a crosslinker between diblock copoly-
mers.105 In this system, the Bi(PEG-PLA)–Pt(IV) conjugate was
obtained by crosslinking two PEG-b-PLA block copolymers by
one Pt(IV) prodrug via pH-responsive hydrazone bonds
(Fig. 11). The amphiphilic Bi(PEG-PLA)–Pt(IV) could self-assem-
ble into micelles. This pH-responsive micelle showed a rapid
release of cisplatin in acidic pH, which contributed to the
increased cytotoxicity compared to free cisplatin. The strategy
involving the use of a Pt(IV) prodrug as a crosslinker was
extended to develop shell- or core-crosslinked micelles for sta-
bilizing the micelle structure and preventing the premature
release of the drug. Song et al. reported shell-crosslinked
mPEG-b-PCL-b-PLL micelles based on a dicarboxyl Pt(IV)
prodrug.106 Two axial succinic moieties of the Pt(IV) prodrug
could react via EDC/NHS chemistry with free amine groups in
the PLL segment occupying the hydrophilic shell of the
micelles. Compared with free cisplatin and prodrugs, shell-
crosslinked micelles not only showed a sustained release of
cisplatin with enhanced cytotoxicity in vitro, but also exhibited
selective accumulation into tumor sites in vivo.
7. Conclusions
Since the successful clinical transfer of cisplatin and oxalipla-
tin, various Pt-based drugs have been developed and they have
shown significant antitumor eﬀects in vitro. Nevertheless,
most free Pt-based drugs have failed to enter clinical use due
to the severe side eﬀects and lower activity than cisplatin. Poly-
meric nanoparticles have emerged as one of the alternative
strategies for overcoming the disadvantages of bare Pt-based
drugs. For example, the NC-6004 micelle comprised of cispla-
tin-conjugated PEG-b-poly(glutamic acid) (PEG-b-P(Glu)) was
developed by Kataoka’s group and has shown reduced nephro-
toxicity and improved antitumor eﬃcacy in pancreatic cancer.
This is currently in a Phase III clinical trial.10–12,107 Inspired by
the successful development of NC-6004, NC-4016 was also
developed by conjugating DACHPt with the PEG-b-P(Glu).
NC-4016 has also shown potential therapeutic eﬃcacy in
various tumor models and is currently in a Phase I clinical
trial.10–12,108,109 ProlindacTM (AP5346) is one of the polymer-Pt
(II) conjugates, which contains DACHPt conjugated with N-(2-
hydroxypropyl)methacrylamide (HPMA) via a pH-sensitive
coordinating group. This is currently in Phase II clinical
studies for advanced ovarian cancer.10,12,110 In addition to the
polymeric delivery systems, various liposomal nanoparticles
containing Pt-based drugs have been reported for the clinical
trials.10,111–113 The increasing number of Pt-based drug deliv-
ery systems under clinical evaluation have motivated many
researchers to develop a more advanced strategy for eﬀective
anticancer therapy.
Fig. 11 (A) Structure of the Bi(PEG-PLA)-Pt(IV) polymer–prodrug conju-
gate. (B) Schematic illustration of the preparation and operation of the
pH-responsive Pt(IV) delivery system. Bi(PEG-PLA)-Pt(IV) NPs were
formed through self-assembly of polymer–drug conjugates. Under
acidic conditions, the hydrazine bonds were hydrolyzed, resulting in the
rapid release of cisplatin (reproduced from ref. 105 with permission from
the American Chemical Society).
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In this review, we have summarized and discussed the pro-
gress attained in the development of polymeric nanoparticles
for eﬀective delivery of Pt-based drugs, focusing on drug con-
figurations and incorporation methods. Whereas micelles have
been the most employed systems in the past five years, stan-
dard techniques such as desolvation, emulsion, and nanopre-
cipitation have also been frequently used for the delivery of Pt-
based drugs. Crosslinking strategies and integration of target-
ing ligands have also been employed to improve the loading
eﬃciency and the tumor accumulation of drugs. Co-delivery of
other therapeutic agents or chemosensitizers has provided a
method for overcoming the resistance to cisplatin. In particu-
lar, unique polymeric nanoparticles like metallosomes and
PCN have been developed as potential routes to improve anti-
cancer eﬀects and mitigate side eﬀects. Most strategies
described in this review oﬀer rational alternatives to existing
conventional methods. These eﬀorts are expected to pave the
way for the practical advancement and clinical use of Pt-based
anticancer therapy.
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